Cleveland, Ohio (PRWEB) July 10, 2014
Understanding the need for better quality and higher consistency in ion channel-expressing cell lines, and the gap that currently exists in this area, ChanTest has recently developed new cells that expand its industry-leading portfolio of validated ion channel and GPCR cell lines. ChanTest’s research focuses on ion channel-expressing cell lines, as ion channels control many critical physiological functions throughout the body. Being able to control this activity creates the potential to treat a variety of human diseases.
ChanTest has validated these cells using their automated electrophysiology and fluorescent plate reader systems.
Because of their control over many critical physiological functions, ion channels are one of the most important categories of drug targets in the pharmaceutical industry. With the growing need to test the safety and efficiency of new drugs, the importance of an organized library of cell lines is critical.
ChanTest’s cell and molecular biology group has developed several new or improved recombinant cells expressing ligand-gated ion channels. Two of these new products, CTN6117 (stably transfected) and CTN7117 (transiently transfected), consist of ionotropic serotonergic (5-HT3A) receptors expressed in HEK293 cells. 5-HT3A is a therapeutic target in nausea and irritable bowel syndrome. Also, new cell lines have been developed that stably express nicotinic acetylcholine receptor subtypes in CHO cells. These include a3ß4a5 (CT6024) and a2ß4 (CT6023), which are important therapeutic targets in several neurological indications, and join previously developed nicotinic a7 (CT6201) and a3ß4 (CT6021) subtype-expressing cell lines in our catalog. ChanTest has engineered all cells for optimal performance in automated patch clamp and FLIPR high throughput screening systems.
In combination with automated medium- to high-throughput functional ass
Copyright©2014 Vocus, Inc.
All rights reserved